Overview

A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects

Status:
Completed

Trial end date:
2017-09-24

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to demonstrate that macitentan and tadalafil administered as a fixed combination is bioequivalent to both compounds given as separate tablets given at the same doses as in the fixed combination (i.e. whether the amounts of macitentan and tadalfil which reach the blood are comparable).

Phase:

Phase 1

Details

Lead Sponsor:

Actelion

Treatments:

Macitentan
Tadalafil